With over 15 years of experience in immunology and infectious diseases, this background is foundational to leading advancements in clinical trials for immune-related therapeutics. The expertise spans conducting pivotal vaccine studies and detailed immune response profiling in conditions like Ebola virus disease, COVID-19, and influenza. Proficient in developing innovative blood immune profiling assays and optimizing clinical sample logistics, the strategic approach to implementing operations in commercial laboratory settings underscores a commitment to pioneering advancements in the field of immunology.

With a robust expertise in conducting large-scale screens and managing large data sets and sample sizes, this background is marked by a proven track record in efficiently handling multiple complex projects. Demonstrated leadership skills include supervising teams and students to successfully deliver projects, ensuring optimal communication and team coordination. The capacity to lead and manage intricate systems is further evidenced by adeptness in streamlining operations and driving strategic initiatives, showcasing a strong foundation for overseeing comprehensive organizational functions.

With over 12 years of experience studying the human immune system and 7 years in developing multiparameter technologies, this background is instrumental in advancing solutions in two key areas: prioritizing molecular targets and enhancing the throughput and robustness of technology. This expertise supports the strategic development and optimization of innovative solutions.

Having been a faculty member at Stanford since 2004, expertise has been developed through collaboration with a large network of scientists, focusing on biological processes integral to advancing company goals. Additionally, the co-founding of "DISCO Pharmaceuticals" in 2023 highlights a commitment to innovation and leadership in the pharmaceutical industry.

Having initiated companies such as Rigel, Nodality, BINA, Apprise, IonPath, Akoya, and CytoBank, and played a crucial role in the development of DVS/CyTOF, this track record includes significant contributions to the commercial sector, with three of these companies achieving sales or IPOs of over $100M. The Stanford lab has been a hub for developing pioneering technologies in cell analysis and gene transfer, both clinically and for biomedical research. With more than 200 publications, many of which focus on the practical development of technologies poised for commercial robustness, there is a demonstrated ability to transform innovative ideas into commercial success.